



ADVERSE DRUG REACTIONS, INCLUDING SJS, TEN

CUTANEOUS ADVERSE DRUG REACTION TO PONATINIB THERAPY FOR CHRONIC MYELOGENOUS LEUKAEMIA

Martina Zussino⁽¹⁾ - Michela Brena⁽¹⁾ - Gianluca Tadini⁽²⁾ - Antonella Coggi⁽¹⁾ - Raffaele Gianotti⁽¹⁾

Fondazione Irccs Ospedale Maggiore Ca'granda, U.o Dermatologia, Dipartimento Di Fisiopatologia Medico-chirurgica E Dei Trapianti, Università Degli Studi Di Milano, Milan, Italy⁽¹⁾ - Fondazione Irccs Ospedale Maggiore Ca'granda, U.o Dermatologia Pediatrica, Dipartimento Di Fisiopatologia Medico-chirurgica E Dei Trapianti, Università Degli Studi Di Milano, Milan, Italy⁽²⁾

Background: Ponatinib is a third-generation tyrosine kinase inhibitor, with demonstrated efficacy in chronic myelogenous leukaemia (CML) and Philadelphia chromosome-positive acute lymphocytic leukaemia (ALL). As with other tyrosine kinase inhibitors, several cutaneous adverse events have been reported in the literature.

Observation: We present a case of ichthyosiform pityriasis rubra pilaris-like eruption in a 62 years old female patient affected by chronic myelogenous leukaemia from 2015. After an initial therapy with Nilotinib, she was turned to Ponatinib in 2017 achieving minimal residual disease (MRD) but developing erythematous and hyperkeratotic patches with areas of atrophy and sharp borders.

Key message: Cutaneous drug adverse events are common, especially in oncologic field and sometimes they can force clinicians to stop or change therapy. It is important to be aware of what kind of cutaneous reaction we are facing and how to manage it. Pityriasis rubra pilaris (PRP)-like eruptions can be easily treated with acitretin or even topical retinoids, without stopping a lifesaving therapy.

